A share price of Syndax Pharmaceuticals Inc [SNDX] is currently trading at $15.74, up 6.86%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SNDX shares have gain 26.12% over the last week, with a monthly amount glided 62.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on August 05, 2025, when BTIG Research reiterated its Buy rating and also boosted its price target to $56 from $43. Previously, Goldman started tracking the stock with Buy rating on July 10, 2025, and set its price target to $18. On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $37 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $37 on June 28, 2024. Scotiabank downgraded its rating to a Sector Perform and reduced its price target to $23 on January 31, 2024. Mizuho started tracking with a Buy rating for this stock on December 22, 2023, and assigned it a price target of $45. In a note dated October 25, 2023, BofA Securities initiated an Buy rating and provided a target price of $29 on this stock.
Syndax Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $8.58 and $22.50. Currently, Wall Street analysts expect the stock to reach $26.5 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $15.74 at the most recent close of the market. An investor can expect a potential return of 68.36% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
Trailing Twelve Months sales for Syndax Pharmaceuticals Inc [NASDAQ:SNDX] were 78.18M which represents 984.51% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -4.34%, Pretax Profit Margin comes in at -4.28%, and Net Profit Margin reading is -4.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -1.3 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.03 points at the first support level, and at 14.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.21, and for the 2nd resistance point, it is at 16.69.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Syndax Pharmaceuticals Inc [NASDAQ:SNDX] is 4.71. Further, the Quick Ratio stands at 4.55, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 17.34, the price to book ratio is 8.60.
Transactions by insiders
Recent insider trading involved DENNIS G PODLESAK, Director, that happened on Aug 14 ’25 when 43200.0 shares were purchased. Chief Financial Officer, Goldan Keith A. completed a deal on Jul 16 ’25 to sell 1296.0 shares. Meanwhile, Chief Executive Officer Metzger Michael A sold 7534.0 shares on Jul 16 ’25.
